Lilly Saw Pandemic-Related Benefits In Q1, Expects Headwinds Long Term

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The pharma saw a $250m revenue increase due to inventory stockpiling and early prescription renewals, but its therapies outside cancer and diabetes may suffer in the coming quarters due to COVID-19.

business documents accounting with calculator and magnifying glass. concept for financial
Lilly's strong first quarter benefited from pandemic-related stocking and early prescription renewals

Eli Lilly & Co. chairman and CEO David Ricks kicked off the pharma’s first quarter earnings call on 23 April with a lengthy discussion of the disruption the novel coronavirus pandemic has caused within and outside the world of biopharmaceuticals. The Indianapolis-based firm saw some revenue benefit from the pandemic during Q1, he said, but noted COVID-19 will take more of a toll on the company’s business during the rest of the year.

Lilly brought in an estimated $250m more in revenue during the first quarter due from purchases motivated by fear of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.